GRB17
antibody from Invitrogen Antibodies
Targeting: GZMB
CCPI, CGL-1, CGL1, CSP-B, CSPB, CTLA1, CTSGL1, HLP, SECT
Antibody data
- Antibody Data
- Antigen structure
- References [19]
- Comments [0]
- Validations
- Other assay [5]
Submit
Validation data
Reference
Comment
Report error
- Product number
- GRB17 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- Granzyme B Monoclonal Antibody (GB11), PE-Texas Red
- Antibody type
- Monoclonal
- Antigen
- Other
- Description
- According to the literature this antibody recognizes the serine protease, granzyme B1. This enzyme is involved in apoptotic cell death. Granzyme B, as well as other enzymes contained in lytic granules, is released primarily by cytotoxic T lymphocytes (CTLs). In addition to immunostaining for flow cytometry, the GB11 mAb has been shown to be useful as an ELISA capture antibody.
- Reactivity
- Human
- Host
- Mouse
- Isotype
- IgG
- Antibody clone number
- GB11
- Vial size
- 500 µL
- Storage
- 4° C
Submitted references Limited impact of fingolimod treatment during the initial weeks of ART in SIV-infected rhesus macaques.
A Personalized Neoantigen Vaccine in Combination with Platinum-Based Chemotherapy Induces a T-Cell Response Coinciding with a Complete Response in Endometrial Carcinoma.
Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques.
Baricitinib treatment resolves lower airway inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques.
Analysis of tumor-infiltrating NK and T cells highlights IL-15 stimulation and TIGIT blockade as a combination immunotherapy strategy for soft tissue sarcomas.
Deciphering the Mechanisms of Improved Immunogenicity of Hypochlorous Acid-Treated Antigens in Anti-Cancer Dendritic Cell-Based Vaccines.
Differential Effect of Mucosal NKp44(+) Innate Lymphoid Cells and Δγ Cells on Simian Immunodeficiency Virus Infection Outcome in Rhesus Macaques.
Circulating CD56(bright) NK cells inversely correlate with survival of melanoma patients.
The Effectiveness of Checkpoint Inhibitor Combinations and Administration Timing Can Be Measured by Granzyme B PET Imaging.
50-Gy Stereotactic Body Radiation Therapy to the Dominant Intraprostatic Nodule: Results From a Phase 1a/b Trial.
Long-Term Persistence of Exhausted CD8 T Cells in Chronic Infection Is Regulated by MicroRNA-155.
Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus.
PD-1 Blockade Unleashes Effector Potential of Both High- and Low-Affinity Tumor-Infiltrating T Cells.
Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy.
PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy.
miR-150 Regulates Memory CD8 T Cell Differentiation via c-Myb.
Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity.
IL-2 in the tumor microenvironment is necessary for Wiskott-Aldrich syndrome protein deficient NK cells to respond to tumors in vivo.
A CD8α(-) subpopulation of macaque circulatory natural killer cells can mediate both antibody-dependent and antibody-independent cytotoxic activities.
Pino M, Pagliuzza A, Pampena MB, Deleage C, Viox EG, Nguyen K, Shim I, Zhang A, Harper JL, Samer S, King CT, Cervasi B, Gill KP, Ehnert S, Jean SM, Freeman ML, Lifson JD, Kulpa D, Betts MR, Chomont N, Lederman MM, Paiardini M
Nature communications 2022 Aug 27;13(1):5055
Nature communications 2022 Aug 27;13(1):5055
A Personalized Neoantigen Vaccine in Combination with Platinum-Based Chemotherapy Induces a T-Cell Response Coinciding with a Complete Response in Endometrial Carcinoma.
Harari A, Sarivalasis A, de Jonge K, Thierry AC, Huber F, Boudousquie C, Rossier L, Orcurto A, Imbimbo M, Baumgaertner P, Bassani-Sternberg M, Kandalaft LE
Cancers 2021 Nov 18;13(22)
Cancers 2021 Nov 18;13(22)
Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques.
Hoang TN, Pino M, Boddapati AK, Viox EG, Starke CE, Upadhyay AA, Gumber S, Nekorchuk M, Busman-Sahay K, Strongin Z, Harper JL, Tharp GK, Pellegrini KL, Kirejczyk S, Zandi K, Tao S, Horton TR, Beagle EN, Mahar EA, Lee MYH, Cohen J, Jean SM, Wood JS, Connor-Stroud F, Stammen RL, Delmas OM, Wang S, Cooney KA, Sayegh MN, Wang L, Filev PD, Weiskopf D, Silvestri G, Waggoner J, Piantadosi A, Kasturi SP, Al-Shakhshir H, Ribeiro SP, Sekaly RP, Levit RD, Estes JD, Vanderford TH, Schinazi RF, Bosinger SE, Paiardini M
Cell 2021 Jan 21;184(2):460-475.e21
Cell 2021 Jan 21;184(2):460-475.e21
Baricitinib treatment resolves lower airway inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques.
Hoang TN, Pino M, Boddapati AK, Viox EG, Starke CE, Upadhyay AA, Gumber S, Busman-Sahay K, Strongin Z, Harper JL, Tharp GK, Pellegrini KL, Kirejczyk S, Zandi K, Tao S, Horton TR, Beagle EN, Mahar EA, Lee MY, Cohen J, Jean SM, Wood JS, Connor-Stroud F, Stammen RL, Delmas OM, Wang S, Cooney KA, Sayegh MN, Wang L, Weiskopf D, Filev PD, Waggoner J, Piantadosi A, Kasturi SP, Al-Shakhshir H, Ribeiro SP, Sekaly RP, Levit RD, Estes JD, Vanderford TH, Schinazi RF, Bosinger SE, Paiardini M
bioRxiv : the preprint server for biology 2020 Sep 16;
bioRxiv : the preprint server for biology 2020 Sep 16;
Analysis of tumor-infiltrating NK and T cells highlights IL-15 stimulation and TIGIT blockade as a combination immunotherapy strategy for soft tissue sarcomas.
Judge SJ, Darrow MA, Thorpe SW, Gingrich AA, O'Donnell EF, Bellini AR, Sturgill IR, Vick LV, Dunai C, Stoffel KM, Lyu Y, Chen S, Cho M, Rebhun RB, Monjazeb AM, Murphy WJ, Canter RJ
Journal for immunotherapy of cancer 2020 Nov;8(2)
Journal for immunotherapy of cancer 2020 Nov;8(2)
Deciphering the Mechanisms of Improved Immunogenicity of Hypochlorous Acid-Treated Antigens in Anti-Cancer Dendritic Cell-Based Vaccines.
Graciotti M, Marino F, Pak H, Baumgaertner P, Thierry AC, Chiffelle J, Perez MAS, Zoete V, Harari A, Bassani-Sternberg M, Kandalaft LE
Vaccines 2020 Jun 2;8(2)
Vaccines 2020 Jun 2;8(2)
Differential Effect of Mucosal NKp44(+) Innate Lymphoid Cells and Δγ Cells on Simian Immunodeficiency Virus Infection Outcome in Rhesus Macaques.
Rahman MA, Ko EJ, Enyindah-Asonye G, Helmold Hait S, Hogge C, Hunegnaw R, Venzon DJ, Hoang T, Robert-Guroff M
Journal of immunology (Baltimore, Md. : 1950) 2019 Nov 1;203(9):2459-2471
Journal of immunology (Baltimore, Md. : 1950) 2019 Nov 1;203(9):2459-2471
Circulating CD56(bright) NK cells inversely correlate with survival of melanoma patients.
de Jonge K, Ebering A, Nassiri S, Maby-El Hajjami H, Ouertatani-Sakouhi H, Baumgaertner P, Speiser DE
Scientific reports 2019 Mar 14;9(1):4487
Scientific reports 2019 Mar 14;9(1):4487
The Effectiveness of Checkpoint Inhibitor Combinations and Administration Timing Can Be Measured by Granzyme B PET Imaging.
Larimer BM, Bloch E, Nesti S, Austin EE, Wehrenberg-Klee E, Boland G, Mahmood U
Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Feb 15;25(4):1196-1205
Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Feb 15;25(4):1196-1205
50-Gy Stereotactic Body Radiation Therapy to the Dominant Intraprostatic Nodule: Results From a Phase 1a/b Trial.
Herrera FG, Valerio M, Berthold D, Tawadros T, Meuwly JY, Vallet V, Baumgartner P, Thierry AC, De Bari B, Jichlinski P, Kandalaft L, Coukos G, Harari A, Bourhis J
International journal of radiation oncology, biology, physics 2019 Feb 1;103(2):320-334
International journal of radiation oncology, biology, physics 2019 Feb 1;103(2):320-334
Long-Term Persistence of Exhausted CD8 T Cells in Chronic Infection Is Regulated by MicroRNA-155.
Stelekati E, Chen Z, Manne S, Kurachi M, Ali MA, Lewy K, Cai Z, Nzingha K, McLane LM, Hope JL, Fike AJ, Katsikis PD, Wherry EJ
Cell reports 2018 May 15;23(7):2142-2156
Cell reports 2018 May 15;23(7):2142-2156
Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus.
Oseledchyk A, Ricca JM, Gigoux M, Ko B, Redelman-Sidi G, Walther T, Liu C, Iyer G, Merghoub T, Wolchok JD, Zamarin D
Oncotarget 2018 Jun 19;9(47):28702-28716
Oncotarget 2018 Jun 19;9(47):28702-28716
PD-1 Blockade Unleashes Effector Potential of Both High- and Low-Affinity Tumor-Infiltrating T Cells.
Martínez-Usatorre A, Donda A, Zehn D, Romero P
Journal of immunology (Baltimore, Md. : 1950) 2018 Jul 15;201(2):792-803
Journal of immunology (Baltimore, Md. : 1950) 2018 Jul 15;201(2):792-803
Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy.
Ricca JM, Oseledchyk A, Walther T, Liu C, Mangarin L, Merghoub T, Wolchok JD, Zamarin D
Molecular therapy : the journal of the American Society of Gene Therapy 2018 Apr 4;26(4):1008-1019
Molecular therapy : the journal of the American Society of Gene Therapy 2018 Apr 4;26(4):1008-1019
PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy.
Zamarin D, Ricca JM, Sadekova S, Oseledchyk A, Yu Y, Blumenschein WM, Wong J, Gigoux M, Merghoub T, Wolchok JD
The Journal of clinical investigation 2018 Apr 2;128(4):1413-1428
The Journal of clinical investigation 2018 Apr 2;128(4):1413-1428
miR-150 Regulates Memory CD8 T Cell Differentiation via c-Myb.
Chen Z, Stelekati E, Kurachi M, Yu S, Cai Z, Manne S, Khan O, Yang X, Wherry EJ
Cell reports 2017 Sep 12;20(11):2584-2597
Cell reports 2017 Sep 12;20(11):2584-2597
Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity.
Zamarin D, Holmgaard RB, Ricca J, Plitt T, Palese P, Sharma P, Merghoub T, Wolchok JD, Allison JP
Nature communications 2017 Feb 13;8:14340
Nature communications 2017 Feb 13;8:14340
IL-2 in the tumor microenvironment is necessary for Wiskott-Aldrich syndrome protein deficient NK cells to respond to tumors in vivo.
Kritikou JS, Dahlberg CI, Baptista MA, Wagner AK, Banerjee PP, Gwalani LA, Poli C, Panda SK, Kärre K, Kaech SM, Wermeling F, Andersson J, Orange JS, Brauner H, Westerberg LS
Scientific reports 2016 Aug 1;6:30636
Scientific reports 2016 Aug 1;6:30636
A CD8α(-) subpopulation of macaque circulatory natural killer cells can mediate both antibody-dependent and antibody-independent cytotoxic activities.
Vargas-Inchaustegui DA, Demberg T, Robert-Guroff M
Immunology 2011 Nov;134(3):326-40
Immunology 2011 Nov;134(3):326-40
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 7 WAS patient spleen NK cells have altered receptor expression. ( A ) CD56 expression on healthy PBMCs, healthy splenocytes, and WAS patient splenocytes, plotted against CD3 in the plots and as MFI in the histograms. ( B ) CD69 and DNAM-1 surface expression, and Granzyme B and Perforin intracellular content in healthy PBMCs, healthy splenocytes, and WAS patient splenocytes. ( C ) Degranulation, as measured by CD107a surface expression and IFNgamma production in healthy PBMCs, healthy splenocytes, and WAS patient splenocytes shown in contour plots ( left ) and a bar graph ( right ). ( D - F ) Expression analysis and survival of neuroblastoma patients in the R2 database, (R2: Genomics Analysis and Visualization Platform; http://r2.amc.nl ). n = 498 ( D ) Correlation of WASp and IL-2 expression in neuroblastoma patients. Each patient is represented by circles for WASp expression (black circle; left Y-axis) and IL-2 expression (grey circle; right Y-axis). ( E , F ) Survival curves of ( E ) neuroblastoma patients and ( F ) diffuse large B cell lymphoma patients with high WASp expression (blue) and low WASp expression (red). Survival curves of ( E ) neuroblastoma patients and ( F ) diffuse large B cell lymphoma patients with high IL-2 expression (blue) and low IL-2 expression (red).
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure S7 Baricitinib treatment did not affect the immune T cell responses in SARS-CoV-2-infected RMs, related to Figure 6 (A-C) Frequency of circulating CD4+ T cells spontaneously (without stimulation) producing pro-inflammatory Th17 related cytokines (A) IL-17 + , (B) IL-17 + IL-21 + , (C) IL-17 + IL- 22 + at necropsy (days 10-11 after infection) in baricitinib (blue) and untreated (red) SARS-CoV-2 infected RMs. (D) Representative flow cytometry staining of IFNgamma, TNFalpha, IL-2, IL-4 and IL-17a in CD4 + and CD8 + T cells of a SARS-CoV-2 infected RM following stimulation with SARS-CoV-2 S peptide pool. IFNgamma, Unstimulated background values were subtracted from S peptide stimulated values to determine T cell cytokine. (E and F) IFNgamma, TNFalpha, IL-2, IL-4 and IL-17a frequency levels in (E) CD4 + and (F) CD8 + T cells following stimulation with SARS-CoV-2 S peptide pool. (G-L) IFNgamma, TNFalpha, IL-2, IL-4 and IL-17a frequency levels in (G) CD4 + and (H) CD8 + T cells following stimulation with PMA/Ionomycin. Values from unstimulated controls were subtracted in all cases. Granzyme B and PD-1 levels in (I and J) blood and (K and L) BAL memory CD8 + T cells measured by flow cytometry. Each symbol represents individual animals. Thick lines represent the average of the baricitinib treated (blue line), and untreated groups (red line). Bars represent the average of the treated and untreated groups. Statistical analysis was performed using a non-parametric Mann-Whitney Tes
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 6 Proof-in-concept that inhaled IL-15 drives peripheral NK and CD8 + T cell activation and TIGIT upregulation in dogs with metastatic osteosarcoma. (A) Schema for our first-in-dog clinical trial of inhaled IL-15 in dogs with naturally occurring metastatic osteosarcoma. (B) Representative flow cytometry showing peripheral blood CD45 + , lymphocytes, CD3, CD3 - NKp46 + NK, and CD3 + CD8 + T cell populations. (C-D) Inhaled IL-15 stimulates peripheral cytotoxic lymphocytes in vivo leading to upregulation of granzyme B and Ki67 by flow cytometry analysis. (E-F) Fold change in granzyme B expression significantly increased on NK cells (p=0.01) and fold change in Ki67 expression significantly increased on T cells (p=0.03). (G) RNA sequencing analysis of CD5-depleted NK cells from three dogs on-trial showing TIGIT upregulation in 2/3 patients. Mean+-SEM. P values determined using paired Student's t-test. Fold change comparison using Pre Tx value of 1. IL-15, interleukin 15; NK, natural killer; On Tx, on treatment; Pre Tx, pretreatment.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Fig. 2 FTY720 treatment in the first weeks of ART retains cytolytic cells but does not enhance their functionality in the LN. a Frequency of CD4+ T cells, b CD8+ T cells, and ( c ) ratio of CD4+/CD8+ T cells in lymph node (LN) mononuclear cells at baseline (week -1) and at 8 weeks of treatment in early FTY720 ( n = 8 RMs) or control (n = 14 RMs) SIV-infected RMs. d Frequency of LN perforin+ (Perf+), e granzyme B (GrB+), and ( f ) Perf+GrB+ CD8+ T cells at baseline (week -1) and at 8 weeks in early FTY720 (red) or control (black) SIV-infected RMs. g Fold reduction between week -1 and week 8 of Perf+GrB+ CD8+ T cells, and ( h ) frequency of LN CD8+ T cells expressing CXCR5 at baseline (week -1) and at 8 weeks in early FTY720 ( n = 8 RMs) and control ( n = 14 RMs) SIV-infected RMs. i Representative flow cytometry staining of P185 mastocytoma target cells (TFL4+ cells) expressing active caspase-3 when cultured alone or co-cultured with different ratios of effector CD8+ T cells derived from LN. j Frequency of target cells expressing active caspase 3 following co-culture with CD8+ T cells derived from LN at week 8 from early FTY720 ( n = 8 RMs) or control ( n = 7 RMs) SIV-infected RMs. k Representative flow cytometry staining of CD56-CD16+NK+ cells in LN at week -1 and 8 from early FTY720 (top) or control SIV-infected RMs (bottom). l Frequency of CD56-CD16+ NK cells and ( m ) CD16 geometric mean fluorescence intensity (geomean) in NK cells derived from LN at week -1 and 8 from earl
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 4 NDV induces increased immune infiltration and delay of tumor growth in treated and distant tumors Animals bearing bilateral flank MB49 bladder tumors were treated with 3 injections of NDV administered every other day into right tumor. ( A - D ) The tumors were collected 3 days after last treatment and analyzed by flow cytometry. (A) Representative flow cytometry plots showing proportion of CD4+ and CD8+ cells (% of all live single cells) (top) and proportion of Foxp3- and FoxP3+ CD4 cells (% of all CD4) (bottom) in tumors treated with PBS (left) or NDV (right). (B) T cell infiltration in the treated tumors and expression of activation (ICOS), lytic (GrB), and proliferation (Ki-67) markers by the CD8 and Tcon lymphocytes from treated tumors. (C) Representative flow cytometry plots showing proportion of CD4+ and CD8+ cells (%of all live single cells) (top) and proportion of Foxp3- and FoxP3+ CD4 cells (%of all CD4) (bottom) in distant tumors of mice treated with PBS (left) or NDV (right). (D) T cell infiltration in the distant tumors and expression of activation (ICOS), lytic (Granzyme B), and proliferation (Ki-67) markers by the CD8 and Tcon lymphocytes from distant tumors. ( E - G ) Animals bearing bilateral flank MB49 bladder tumors were treated with 4 injections of NDV administered every other day into right tumor. (E) Treatment schema. (F) Growth of treated and distant tumors and mean tumor growth curves (+- SEM) compared at day 21 post treatment. (G) Overall